BBPOS
25.5.2016 10:01:37 CEST | Business Wire | Press release
BBPOS has announced the launch of WisePadTM 2; advanced technology developed by innovative engineers. The WisePadTM 2 can be used in an integrated or semi-integrated POS environment as well as a stand-alone environment connecting to the payment processor or gateway via GPRS, 3G or Wi-Fi.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160525005100/en/
WisePadTM 2 reads EMV chip card, triple track magnetic stripe card, NFC card and has a secured PIN pad. Compact and lightweight at 3.7oz (105g), it is mobile and flexible. The WisePadTM 2 also has standard over-the-air features allowing both firmware updates and key injection that are essential in increasing operational efficiency as well as having a 2G/3G modem to allow direct connectivity to the network.
WisePadTM 2 complies with all major industrial security standards including PCI PTS v4.1 with SRED; EMV L1 & L2; EMV Contactless L1; VISA payWave; MasterCard PayPass; AMEX ExpressPay; Discover D-PAS; and MasterCard TQM.
WisePadTM 2 will be widely adopted as a mobile solution working with a smart device or as a stand-alone solution. It will also be a good alternative to conventional counter-top POS devices in countries which use Chip and PIN payment systems, such as China and in Europe. The non-NFC versions have been used at a number of key events and by merchants. For example, at the Dubai World Cup, customers had the flexibility and convenience of not waiting in long queues to purchase tickets and, instead, were able to use their debit or credit cards via roaming staff who were using tablets and WisePadTM .
WisePadTM 2 is the future of mPOS - delivering a cost effective solution with convenient updating and a wide range of applications. Please visit our website for more details.
BBPOS
www.bbpos.com
WisePadTM
2
http://bbpos.com/files/bbproducts/11-WP2_A4_Catalogue_20160523.pdf
About BBPOS
Founded in 2008, BBPOS is an mPOS solution provider headquartered in Hong Kong with regional offices in San Jose, Miami, London, Singapore and Shanghai. The business invented the mobile payment audio jack at a time when smart phones were in their infancy. Today, we are respected as a leading innovator, designer, and manufacturer of end-to-end mobile POS solutions, serving key sectors including mobile merchant, retail, hospitality, delivery, transport and government.
Our world-class engineering team has developed a family of innovative POS devices that deliver quality solutions while implementing the highest security standards. Our products are designed with the flexibility to securely manage any transaction, in any environment, anywhere in the world. In March 2016, mPOS tracker ranked BBPOS 6th among 212 global payment industry players with a high score of 70.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525005100/en/
Contact:
BBPOS
Gloria Chan, +852-3907-0305
gloria.chan@bbpos.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom